Leading the Next Evolution of Immunotherapies
51 - 200
π° $100M Post-IPO Equity on 2022-09
May 3
51 - 200
πΊπΈ United States β Remote
π° $100M Post-IPO Equity on 2022-09
β° Full Time
π΄ Lead
π Compliance
May 1
51 - 200
πΊπΈ United States β Remote
π° $100M Post-IPO Equity on 2022-09
β° Full Time
π Senior
π Compliance
March 29
51 - 200
πΊπΈ United States β Remote
π° $100M Post-IPO Equity on 2022-09
β° Full Time
π΄ Lead
βοΈ Operations